🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,254 results for “First” Clear

  1. A Phase 1/2a, First in Human, Open-Label, Multicenter, Dose Escalation Study with Expansion Cohorts to Evaluate the Safety, Tolerability, and Preliminary Activity of LB101 in Subjects with Advanced Solid Tumors

    Centessa Pharmaceuticals plc

    Advanced solid tumors

    phase 2 other active

    1 trial

  2. A Phase I First-in-Human Dose Escalation Trial to Evaluate the Safety and Efficacy of ARI-HER2 (HER2BBz CAR-T Cells) in Patients with HER2Positive Advanced Breast Cancer

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Patients with HER2Positive Advanced Breast Cancer

    phase 2 other active

    1 trial

  3. A phase II trial aiming to investigate the safety and clinical activity of belantamab mafodotin in adult patients with primary immune thrombocytopenia previously treated with a thrombopoietin receptor agonist and/or rituximab after corticosteroid first-line therapy - BONSAI

    Ology Bioservices Ireland LTD

    Primary Immune Thrombocytopenia

    phase 2 other active

    1 trial

  4. AK104, nab-paclitaxel, carboplatin

    First Tracks Biotherapeutics

    Esophageal Squamous Cell Carcinoma

    phase 2 small molecule active

    1 trial

  5. AK105 and anlotinib

    First Tracks Biotherapeutics

    Cervical Cancer

    phase 2 small molecule active

    1 trial

  6. ASC22

    First Tracks Biotherapeutics

    Chronic Hepatitis b

    phase 2 small molecule completed

    1 trial

  7. ASP8951, PACLITAXEL, GEMCITABINE

    Astellas Pharma GmbH

    First Line Treatment in Subjects with Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma.

    phase 2 small molecule active

    1 trial

  8. AUTO CAR T cell therapy

    Autolus GmbH

    Patients Followed for up to 15 Years Following Their First Dose of AUTO CAR T Cell Therapy

    phase 2 mab active

    1 trial

  9. Abatacept s.c.

    First Tracks Biotherapeutics

    Abatacept

    phase 2 small molecule active

    1 trial

  10. Absorbable and moldable skull base support plate

    First Tracks Biotherapeutics

    Sellar Tumor

    phase 2 other active

    1 trial

  11. Ad-HGF

    First Tracks Biotherapeutics

    Myocardial Infarction

    phase 2 small molecule active

    1 trial

  12. Adebellizumab

    First Tracks Biotherapeutics

    Resectable Lung Non-Small Cell Carcinoma

    phase 2 small molecule active

    1 trial

  13. Adebrelimab combined with irinotecan liposomal (II), oxaliplatin, and 5-FU/LV

    First Tracks Biotherapeutics

    Pancreatic Cancer

    phase 2 small molecule active

    1 trial

  14. Adebrelimab+Albumin paclitaxel +Cisplatin

    First Tracks Biotherapeutics

    Locally Advanced Hypopharyngeal Cancer

    phase 2 small molecule active

    1 trial

  15. Adebrelimab, paclitaxel, carboplatin, bevacizumab, fluzoparib

    First Tracks Biotherapeutics

    Platinum-sensitive Relapsed Ovarian Cancer

    phase 2 small molecule active

    1 trial

  16. All-trans Retinoic Acid in combination with the KPD Regimen

    First Tracks Biotherapeutics

    Multiple Myeloma in Relapse

    phase 2 small molecule active

    1 trial

  17. Almonertinib

    First Tracks Biotherapeutics

    EGFR Positive Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  18. Almonertinib

    First Tracks Biotherapeutics

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  19. Ametinib combined with bevacizumab

    First Tracks Biotherapeutics

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  20. An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

    Ipsen Pharma

    Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

    phase 2 other active

    1 trial

  21. Anlotinib

    First Tracks Biotherapeutics

    Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  22. Anlotinib Hydrochloride

    First Tracks Biotherapeutics

    Effect of Drugs

    phase 2 small molecule active

    1 trial

  23. Anlotinib and Sintilimab injection

    First Tracks Biotherapeutics

    Advanced Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  24. Anlotinib+ Liposomal Doxorubicin

    First Tracks Biotherapeutics

    Sarcoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources